[Childhood treatment of paroxysmal supraventricular tachycardia using i.v. adenosine]

Area of Science:

• Pediatric Cardiology
• Clinical Pharmacology
• Cardiac Electrophysiology

Background:

• Paroxysmal supraventricular tachycardia (PSVT) is a common arrhythmia in pediatric patients, particularly infants.
• Established treatments like verapamil and digitalis have limitations in neonates and infants.
• There is a need for safe and effective PSVT treatments in the pediatric population.

Purpose of the Study:

• To evaluate the efficacy and safety of intravenous adenosine as a first-line therapy for PSVT in children.
• To assess adenosine's success rate in converting different types of pediatric PSVT.
• To document the side effect profile and recurrence rates associated with adenosine treatment.

Main Methods:

• An open, multicenter study involving 19 pediatric patients.
• Treatment of 29 episodes of tachycardia with intravenous adenosine as the initial drug.
• Monitoring of conversion rates, side effects, and recurrence patterns.

Main Results:

• Adenosine successfully converted 76% of all PSVT episodes.
• The success rate increased to 87% for tachycardias involving atrioventricular reentry.
• Adenosine's rapid half-life (approx. 15 seconds) limited the duration of transient side effects.
• Recurrences were observed in approximately one-third of the treated cases.

Conclusions:

• Intravenous adenosine is an efficient and safe first-line treatment for PSVT across all pediatric age groups, including neonates and infants.
• Adenosine offers a favorable safety profile due to its short duration of action.
• While effective, the potential for recurrence necessitates careful patient monitoring and management strategies.